Gallene Sciences: a new player onthe generic medicine field

by Groshan Fabiola I try to cover as many topics as I can Gallene Sciences is a relatively new player on thegeneric medicine field in India, succeeding in a short interval to gain a greatposition on the market. The company’s mission is helping people in variousareas and from various backgrounds have easier access to medicine and medicalsupplies, empowering them to live longer and happier lives. The company’s corevalues are transparency, integrity and ethical steps for providing betteraccess to healthcare, medicine and assistance.

One of the leading companies in the industry, GalleneSciences is leading cutting-edge research for developing new medical products, researchbased on both humans and animals. By collaborating with other entities in themedical field, the company aims to deliver affordable and effective productsdesigned to increase life expectancy and the quality of life of thousands andmillions of individuals. Investing enormously in the quality and safety of thepharmaceuticals developed, the company is basing their progress on clinicalresearch and trials. Always aiming to improve their products, the company puts continuousefforts in finding new and interesting collaborations and partnerships. Withmore than three decades in the pharmaceutical industry, Gallene Sciences is aleading voice in terms of development, research and market needs.

The products developed by the company are appropriate forvarious diseases, some of the most dangerous diseases of the century. Forinstance, the incredible research team working for the pharmaceutical company developedover the years, treatments suitable for hypertension, HIV-AIDS, hormoneimbalance, oncology matters, men’s healthcare issues, as well aspharmaceuticals designed for animal use.

One of the rising diseases of the decade is hypertension,and the company succeeded to develop and deliver effective solutions forcombating it. With concerning global statistics regarding hypertension-relateddeaths, especially located in poor and under-developed areas of the globe, GalleneSciences aims to designs affordable generic anti-hypertension pharmaceuticals,make those accessible to an increased number of individuals from differentsocio economic backgrounds.

Also with a more recurrence amongst individuals in poorand underdeveloped countries, and with fewer treatment chances, HIV-AIDSinfections are yet another leading death cause. Access to proper therapeuticinterventions and treatments in these areas is oftentimes limited, and thisrequires for accessible medicine development and procedures. Requirement, whichluckily, is met with success by the products developed by Gallene Sciences. Theproducts developed by the company are easy to use, recognized internationallyfor their HIV-AIDS treatment properties and their accessibility to variouscategories of individuals.

Hormone imbalance leads oftentimes to a series of graveconditions. Acknowledging that many individuals lack the education in terms theimportance of hormones, Gallene Sciences succeeded to developed accessiblepharmaceuticals designed to correct these imbalances. Unlike other expensivemedicine that is claiming to help patients, but comes at high prices, thispharmaceutical company is choosing to adhere to its value and develop genericmedicine, make it accessible to a larger audience and stick to an ethical procedurein the process of developing those.

Available on the manufacturer’s and retailer’s website,interested clients will find more about the company’s motivations fordeveloping accessible and affordable generic pharmaceuticals, as well as moreabout their collaborations and research initiatives. The platform can beaccessed at gallenesciences.com/,or by using the contact details below:

Contact Name: Vivek Narendrakumar Mapara
Company Name: Gallene Sciences
Exact address: Gallene Sciences PVT. LTD.9,
Suramya Complex Ahmedabad, Gujarat 380061, India"
Email: info@gallenesciences.com

Sponsor Ads

• Ad Space Available - Rent it Now!

Created on Sep 21st 2017 04:26. Viewed 229 times.

Comments